Biomarkers of Alzheimer's Disease: The Present and the Future PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Biomarkers of Alzheimer's Disease: The Present and the Future PDF full book. Access full book title Biomarkers of Alzheimer's Disease: The Present and the Future by Sylvain Lehmann. Download full books in PDF and EPUB format.
Author: Sylvain Lehmann Publisher: Frontiers Media SA ISBN: 2889450414 Category : Languages : en Pages : 220
Book Description
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffering from AD is growing rapidly as the population ages worldwide. Memory impairment is usually the earliest clinical and core symptom of this disease. The diagnosis at a late clinical stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. The actual interest of the scientific head-ways is to optimize the diagnosis in prodromal stage of the disease and to propose personalized therapeutic solutions to individual patients. New revised AD diagnostic criteria include early alteration of cerebrospinal fluid (CSF) biomarkers: decrease of amyloïd peptides (Aβ42), and increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for the diagnosis of AD is a major step towards the “molecular” diagnosis and follow-up of the disease. Many issues are however still subject of debate. This e-book provides a comprehensive overview of the state of the art of fluid biomarkers for AD, e.g. which novel biomarkers should be implemented in clinical practice for diagnosis or for monitoring treatment or side effects, which ones are new for AD or related dementias or what is the potential of peripheral blood markers. Moreover, the e-Book provides practical guidelines how to optimally and efficiently develop and validate novel biomarker assays, and to document and control pre-analytical variation.
Author: Sylvain Lehmann Publisher: Frontiers Media SA ISBN: 2889450414 Category : Languages : en Pages : 220
Book Description
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffering from AD is growing rapidly as the population ages worldwide. Memory impairment is usually the earliest clinical and core symptom of this disease. The diagnosis at a late clinical stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. The actual interest of the scientific head-ways is to optimize the diagnosis in prodromal stage of the disease and to propose personalized therapeutic solutions to individual patients. New revised AD diagnostic criteria include early alteration of cerebrospinal fluid (CSF) biomarkers: decrease of amyloïd peptides (Aβ42), and increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for the diagnosis of AD is a major step towards the “molecular” diagnosis and follow-up of the disease. Many issues are however still subject of debate. This e-book provides a comprehensive overview of the state of the art of fluid biomarkers for AD, e.g. which novel biomarkers should be implemented in clinical practice for diagnosis or for monitoring treatment or side effects, which ones are new for AD or related dementias or what is the potential of peripheral blood markers. Moreover, the e-Book provides practical guidelines how to optimally and efficiently develop and validate novel biomarker assays, and to document and control pre-analytical variation.
Author: Ronald Sahyouni Publisher: World Scientific ISBN: 9813109270 Category : Medical Languages : en Pages : 285
Book Description
The book aims to present, educate and inform individuals about Alzheimer's disease in a comprehensive manner. Its scope ranges from the discovery of the disease, epidemiology and basic biological principles underlying it, to advanced stem cell therapies used in the treatment of Alzheimer's. It adopts a 'global' perspective on Alzheimer's disease, and include epidemiological data and science from countries around the world.Alzheimer's disease is a rapidly growing problem seen in every country around the world. This is the first and only comprehensive book to cover Alzheimer's disease, and includes the most updated literature and scientific progress in the field of dementia and Alzheimer's disease research.Most books on the market that focus on Alzheimer's disease are targeted at caregivers as practical advice on how to deal with loved ones with the disease. This book instead is a comprehensive and popular science book that can be read by anyone with an interest in learning more about the disease.Dr. Jefferson Chen MD, PhD, co-author, participated in the world's first surgical clinical trial using shunts to treat Alzheimer's disease. His first-hand involvement in a clinical trial for patients with Alzheimer's disease and experience treating Normal Pressure Hydrocephalus (NPH) which is commonly misdiagnosed as Alzheimer's disease lends a unique perspective.This book with appeal to a wide audience, regardless of their scientific or educational background.
Author: Robert Perneczky Publisher: Springer Nature ISBN: 1071637746 Category : Alzheimer's disease Languages : en Pages : 345
Book Description
Zusammenfassung: This fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer's disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer's disease field are performed. Written for the highly successful Methods in Molecular Biology series, chapters feature the kind of detailed implementation advice that leads to greater success in the lab or clinic. Authoritative and practical, Biomarkers for Alzheimer's Disease Drug Development, Second Edition seeks to inspire and inform future efforts to develop effective treatments for this devastating disease
Author: Ronald Sahyouni Publisher: World Scientific ISBN: 9811235120 Category : Medical Languages : en Pages : 426
Book Description
This book aims to present, educate and inform individuals about Alzheimer's disease in a comprehensive manner. Its scope ranges from the discovery of the disease, epidemiology and basic biological principles underlying it, to advanced stem cell therapies used in the treatment of Alzheimer's. It adopts a 'global' perspective on Alzheimer's disease, and include epidemiological data and science from countries around the world.Alzheimer's disease is a rapidly growing problem seen in every country around the world. This is the first and only comprehensive book to cover Alzheimer's disease, and includes the most updated literature and scientific progress in the field of dementia and Alzheimer's disease research.Most books on the market that focus on Alzheimer's disease are targeted at caregivers as practical advice on how to deal with loved ones with the disease. This book instead is a comprehensive and popular science book that can be read by anyone with an interest in learning more about the disease.Dr Jefferson Chen MD, PhD, co-author, participated in the world's first surgical clinical trial using shunts to treat Alzheimer's disease. His first-hand involvement in a clinical trial for patients with Alzheimer's disease and experience treating Normal Pressure Hydrocephalus (NPH) which is commonly misdiagnosed as Alzheimer's disease lends a unique perspective.This book with appeal to a wide audience, regardless of their scientific or educational background.
Author: Charlotte E. Teunissen Publisher: Humana ISBN: 9781071613214 Category : Medical Languages : en Pages : 236
Book Description
This volume covers the latest methods used in clinical neurochemistry laboratories for both clinical practice and research. Chapters in this book discuss topics such as techniques for cerebrospinal fluid (CSF) collection, pre-analytical processing, and basic CSF analysis; an examination of biomarkers including ELISA and automated immunochemical assays for amyloid and tau markers for Alzheimer’s disease; the analysis of neurofilaments by digital ELISA; and an example of successful novel immunoassay development. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Cerebrospinal Fluid Biomarkers is a valuable resource for clinicians and researchers to use in CSF labs and CSF courses.
Author: Chiara Villa Publisher: MDPI ISBN: 3039439030 Category : Science Languages : en Pages : 442
Book Description
Alzheimer’s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD.
Author: Robert Perneczky Publisher: Humana ISBN: 9781071637739 Category : Medical Languages : en Pages : 0
Book Description
This fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer’s disease field are performed. Written for the highly successful Methods in Molecular Biology series, chapters feature the kind of detailed implementation advice that leads to greater success in the lab or clinic. Authoritative and practical, Biomarkers for Alzheimer’s Disease Drug Development, Second Edition seeks to inspire and inform future efforts to develop effective treatments for this devastating disease.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309178282 Category : Medical Languages : en Pages : 128
Book Description
Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system. Given the promising potential and necessity for neuroscience biomarkers, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened a public workshop and released the workshop summary entitled Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships. The workshop brought together experts from multiple areas to discuss the most promising and practical arenas in neuroscience in which biomarkers will have the greatest impact. The main objective of the workshop was to identify and discuss biomarker targets that are not currently being aggressively pursued but that could have the greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.
Author: Harald Hampel Publisher: Karger Medical and Scientific Publishers ISBN: 3805598025 Category : Medical Languages : en Pages : 200
Book Description
How current biomarkers are modernizing the diagnosis of Alzheimer's disease Expanding knowledge on genetic and epigenetic risk factors is rapidly enhancing our understanding of the complex molecular interactions and systems involved in the pathogenesis of Alzheimer's disease. In this publication, leading experts discuss emerging novel conceptual models of the disease along with advances in the development of surrogate markers that will not only improve the accuracy of diagnostic technologies but also improve the prospects of developing disease-modifying interventions. The novel framework of the disease presented here highlights research on biological markers as well as efforts to validate technologies for early and accurate detection. It also introduces notion of a complex systems dysfunction that extends beyond prevailing ideas derived from the amyloid' or tau' hypotheses. This outstanding publication provides researchers, clinicians, students and other professionals interested in neurodegenerative disorders with a comprehensive update on current trends and future directions in therapy development, with special focus on advances in clinical trial designs.
Author: Sylvain Lehmann
Author: Sylvain Lehmann
Author: Suman Dutta
Author: Ronald Sahyouni
Author: Robert Perneczky
Author: Ronald Sahyouni
Author: Charlotte E. Teunissen
Author: Chiara Villa
Author: Robert Perneczky
Author: Institute of Medicine
Author: Harald Hampel